Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates

US Patent 10912813 · Granted Feb 9, 2021

Estimated economic value: $172,047,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2023
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2023
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2022
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2022
Combination of CD33 antibody drug conjugates with chemotherapeutic agents2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2021
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2020
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2020
Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates2019